Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
Abstract
:1. Introduction
2. Case Report
3. Discussion and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Omer, S.B.; Salmon, D.A.; Orenstein, W.A.; deHart, M.P.; Halsey, N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N. Engl. J. Med. 2009, 360, 1981–1988. [Google Scholar] [CrossRef] [PubMed]
- Sharif, K.; Shoenfeld, Y. All Magic Comes with a Price: A Case of Henoch-Schönlein Purpura Post-influenza Vaccination. Isr Med. Assoc. J. 2020, 22, 648–649. [Google Scholar] [PubMed]
- Shrestha, S.; Khatri, J.; Shakya, S.; Danekhu, K.; Khatiwada, A.P.; Sah, R.; Kc, B.; Paudyal, V.; Khanal, S.; Rodriguez-Morales, A.J. Adverse events related to COVID-19 vaccines: The need to strengthen pharmacovigilance monitoring systems. Drugs Ther. Perspect. 2021, 37, 376–382. [Google Scholar] [CrossRef] [PubMed]
- AlGhoozi, D.A.; AlKhayyat, H.M. A child with Henoch-Schonlein purpura secondary to a COVID-19 infection. BMJ Case Rep. 2021, 14, e239910. [Google Scholar] [CrossRef]
- Felicetti, P.; Trotta, F.; Bonetto, C. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine 2016, 34, 6634–6640. [Google Scholar] [CrossRef]
- Piram, M.; Mahr, A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein): Current state of knowledge. Curr. Opin. Rheumatol. 2013, 25, 171–178. [Google Scholar] [CrossRef] [PubMed]
- van de Perre, E.; Jones, R.B.; Jayne, D.R.W. IgA vasculitis (Henoch–Schönlein purpura): Refractory and relapsing disease course in the adult population. Clin. Kidney J. 2021, 14, 1953–1960. [Google Scholar] [CrossRef]
- Hines, A.M.; Murphy, N.; Mullin, C.; Barillas, J.; Barrientos, J.C. Henoch-Schönlein purpura presenting post COVID-19 vaccination. Vaccine 2021, 39, 4571–4572. [Google Scholar] [CrossRef]
- Ruperto, N.; Ozen, S.; Pistorio, A.; Dolezalova, P.; Brogan, P.; Cabral, D.A.; Cuttica, R.; Khubchandani, R.; Lovell, D.J.; O’Neil, K.M.; et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical. characterisation. Ann. Rheum. Dis. 2010, 69, 790–797. [Google Scholar] [CrossRef]
- Hetland, L.E.; Susrud, K.S.; Lindahl, K.H.; Bygum, A. Henoch-Schönlein purpura: A literature review. Acta Derm. Venereol. 2017, 97, 1160–1166. [Google Scholar] [CrossRef] [Green Version]
- Sugino, H.; Sawada, Y.; Nakamura, M. IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int. J. Mol. Sci. 2021, 22, 7538. [Google Scholar] [CrossRef] [PubMed]
- Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [Google Scholar] [CrossRef]
- Kantor, R.; Galel, A.; Aviner, S. Henoch-Schönlein Purpura Post-Influenza Vaccination in a Pediatric Patient: A Rare but Possible Adverse Reaction to Vaccine. Isr. Med. Assoc. J. 2020, 22, 654–656. [Google Scholar] [PubMed]
- Jariwala, S.; Vernon, N.; Shliozberg, J. Henoch-Schönlein purpura after hepatitis A vaccination. Ann. Allergy Asthma Immunol. 2011, 107, 180–181. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Z.G.; Zheng, Y.; Lu, S.; Hu, Q.; Fang, Y. Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination. Hum. Vaccines Immunother. 2018, 14, 2666–2668. [Google Scholar] [CrossRef] [Green Version]
- Borocco, C.; Lafay, C.; Plantard, I.; Gottlieb, J.; Koné-Paut, I.; Galeotti, C. SARS-CoV-2-associated Henoch-Schönlein purpura in a 13-year-old girl. Arch. Pediatr. 2021, in press. [Google Scholar] [CrossRef] [PubMed]
- Li, N.L.; Papini, A.B.; Shao, T.; Girard, L. Immunoglobulin-A Vasculitis with Renal Involvement in a Patient with COVID-19: A Case Report and Review of Acute Kidney Injury Related to SARS-CoV-2. Can. J. Kidney Health Dis. 2021, 8, 2054358121991684. [Google Scholar] [CrossRef]
- Serafinelli, J.; Mastrangelo, A.; Morello, W.; Cerioni, V.F.; Salim, A.; Nebuloni, M.; Montini, G. Kidney involvement and histological findings in two pediatric COVID-19 patients. Pediatr. Nephrol. 2021, 1–5. [Google Scholar] [CrossRef]
- Hoskins, B.; Keeven, N.; Dang, M.; Keller, E.; Nagpal, R. A Child with COVID-19 and Immunoglobulin A Vasculitis. Pediatr Ann. 2021, 50, e44–e48. [Google Scholar] [CrossRef]
- Allez, M.; Denis, B.; Bouaziz, J.D.; Battistella, M.; Zagdanski, A.M.; Bayart, J. COVID-19-Related IgA Vasculitis. Arthritis Rheumatol. 2020, 72, 1952–1953. [Google Scholar] [CrossRef]
- Kumar, G.; Pillai, S.; Norwick, P.; Bukulmez, H. Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child. BMJ Case Rep. 2021, 14, e242192. [Google Scholar] [CrossRef]
- Suso, A.S.; Mon, C.; Oñate Alonso, I.; Galindo Romo, K.; Juarez, R.C.; Ramírez, C.L. IgA Vasculitis With Nephritis (Henoch-Schönlein Purpura) in a COVID-19 Patient. Kidney Int. Rep. 2020, 5, 2074–2078. [Google Scholar] [CrossRef]
- El Hasbani, G.; Taher, A.T.; Jawad, A.S.M.; Uthman, I. Henoch-Schönlein purpura: Another COVID-19 complication. Pediatr. Dermatol. 2021. [Google Scholar] [CrossRef]
- Sandhu, S.; Chand, S.; Bhatnagar, A.; Dabas, R.; Bhat, S.; Kumar, H. Possible association between IgA vasculitis and COVID-19. Dermatol Ther. 2021, 34, e14551. [Google Scholar] [CrossRef]
- Jacobi, M.; Lancrei, H.M.; Brosh-Nissimov, T.; Yeshayahu, Y. Purpurona: A Novel Report of COVID-19-Related Henoch-Schonlein Purpura in a Child. Pediatr. Infect. Dis. J. 2021, 40, e93–e94. [Google Scholar] [CrossRef]
- Oñate, I.; Ortiz, M.; Suso, A.; Mon, C.; Galindo, K.; Lentisco, C.; Camacho, R.; Sánchez, M.; Oliet, A.; Ortega, O.; et al. Vasculitis ig a con nefritis (púrpura de schönlein-henoch) tras COVID-19: Una serie de casos y revisión de la literatura [Ig a vasculitis with nephritis (henoch-schönlein purpura) after COVID-19: A case series and review of the literature]. Nefrologia 2021. [Google Scholar] [CrossRef] [PubMed]
- Barbetta, L.; Filocamo, G.; Passoni, E.; Boggio, F.; Folli, C.; Monzani, V. Henoch-Schönlein purpura with renal and gastrointestinal involvement in course of COVID-19: A case report. Clin. Exp. Rheumatol. 2021, 39 (Suppl. 129), 191–192. [Google Scholar] [PubMed]
- Huang, Y.; Li, X.J.; Li, Y.Q.; Dai, W.; Shao, T.; Liu, W.Y. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: A case report. BMC Nephrol. 2020, 21, 504. [Google Scholar] [CrossRef] [PubMed]
- Obeid, M.; Fenwick, C.; Pantaleo, G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021. [Google Scholar] [CrossRef]
- Blumberg, S.; Bienfang, D.; Kantrowitz, F.G. A possible association between influenza vaccination and small vessel vasculitis. Arch. Intern. Med. 1980, 140, 847–848. [Google Scholar] [CrossRef]
- Ledford, D.K. Henoch-Schönlein Purpura and Influenza Vaccine. J. Allergy Clin. Immunol. Pract. 2017, 5, 210. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, T.; Onda, H. Henoch-Schönlein purpura with antiphospholipid antibodies following an influenza vaccination. Pediatr. Nephrol. 2001, 16, 458–459. [Google Scholar] [CrossRef]
- Bellanti, J.A. COVID-19 vaccines and vaccine hesitancy: Role of the allergist/immunologist in promotion of vaccine acceptance. Allergy Asthma Proc. 2021. [Google Scholar] [CrossRef]
- Troiano, G.; Nardi, A. Vaccine hesitancy in the era of COVID-19. Public Health 2021, 194, 245–251. [Google Scholar] [CrossRef] [PubMed]
- Rosenblum, H.G.; Hadler, S.C.; Moulia, D.; Shimabukuro, T.T.; Su, J.R.; Tepper, N.K.; Ess, K.C.; Woo, E.J.; Mba-Jonas, A.; Alimchandani, M.; et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices—United States, July 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 1094–1099. [Google Scholar] [CrossRef]
Diagnostic Criteria | Description |
---|---|
Mandatory criterion | Evidence of palpable purpura in the absence of thrombocytopaenia |
Minimum 1 out of 4 supportive criteria | (1) Acute onset diffuse abdominal pain |
(2) Acute onset arthralgia or arthritis | |
(3) Renal involvement in the form of proteinuria or haematuria | |
(4) Histopathological evidence of leucocytoclastic vasculitis or proliferative glomerulonephritis with predominant IgA deposits |
Blood Tests | Value | Reference Ranges |
---|---|---|
Blood Cells Count | ||
Leukocyte | 7.63 × 103/µL | 4.00–10.00 |
Neutrophils | 5.42 × 103/µL | 2.00–7.00 |
Lymphocytes | 1.65 × 103/µL | 1.00–4.00 |
Monocytes | 0.24 × 103/µL | 0.20–1.00 |
Eosinophils | 0.19 × 103/µL | 0.02–0.50 |
Basophils | 0.01 × 103/µL | 0.00–0.20 |
Erythrocyte | 4.75 × 106/µL | 3.8–4.8 |
Platelet | 268 × 103/µL | 150–450 |
Erythrocyte sedimentation rate (ESR) | 36 mm | 1.0–15.0 |
C-reactive protein (CRP) | 40.85 mg/dL | 0.00–5.00 |
Kidney Function | ||
Creatinine | 0.7 mg/dL | 0.5–0.9 |
Liver Function | ||
Aspartate aminotransferase (AST) | 23 U/L | 4–32 |
Alanine aminotransferase (ALT) | 19 U/L | 4–32 |
Coagulation Test | ||
Prothrombin time (PT) | 96% 11.9 s | 70.0–130 10.0–14 |
International normalized ratio (INR) | 10.3 | 0.80–1.30 |
Partial thromboplastin time (PTT) | 25 s | 23 |
Fibrinogen | 280 mg/dL | 200–430 |
Haptoglobin | 120 mg/dL | 50.0–220.0 |
Autoimmune Tests | ||
Antinuclear antibodies (ANA) | Negative | Negative |
Extractable nuclear antigen (ENA) SCREENING (anti-Sm, RNP, Ro60, Ro62, SS-B, SCl-70, Jo-1) | <3.6 U/mL | <20 |
Antineutrophil cytoplasm antibodies (ANCA) directed against myeloperoxidase (MPO) | <3.20 U/mL | <20 |
ANCA-directed against proteinase-3 (PR3) | <2.30 U/mL | <20 |
Antiplatelet antibodies | Absent | Absent |
Anticardiolipin IgG antibodies | 0.40 U/mL | <7 |
Anticardiolipin IgM antibodies | 2 U/mL | <7 |
Anti-β2-glycoprotein IgG antibodies | 0.73 U/mL | <7 |
Anti-β2-glycoprotein IgM antibodies | 0.21 U/mL | <7 |
Anti-double stranded DNA (Anti-dsDNA) antibodies | Negative | Negative |
Immunoglobulins | ||
Cryoglobulin | Absent | Absent |
Immunoglobulin G | 1220 mg/dL | 700.0–1600.0 |
Immunoglobulin A | 325 mg/dL | 70.0–400.0 |
Immunoglobulin M | 107 mg/dL | 40.0–230.0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sirufo, M.M.; Raggiunti, M.; Magnanimi, L.M.; Ginaldi, L.; De Martinis, M. Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report. Vaccines 2021, 9, 1078. https://doi.org/10.3390/vaccines9101078
Sirufo MM, Raggiunti M, Magnanimi LM, Ginaldi L, De Martinis M. Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report. Vaccines. 2021; 9(10):1078. https://doi.org/10.3390/vaccines9101078
Chicago/Turabian StyleSirufo, Maria Maddalena, Martina Raggiunti, Lina Maria Magnanimi, Lia Ginaldi, and Massimo De Martinis. 2021. "Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report" Vaccines 9, no. 10: 1078. https://doi.org/10.3390/vaccines9101078